Systematic Review of Interventions to Reduce Operating Time in Lung Cancer Surgery [0.03%]
缩短肺癌手术时间的干预措施系统评价
Paulien C Hoefsmit,Robert J Cerfolio,Ralph de Vries et al.
Paulien C Hoefsmit et al.
Introduction: Operating rooms are a scarce resource but often used inefficiently. Operating room efficiency emerges as an important part of maximizing surgical capacity and productivity, minimizing delays, and optimizing ...
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors [0.03%]
PARP抑制剂与免疫检查点抑制剂的协同作用
Zhaozhen Wu,Pengfei Cui,Haitao Tao et al.
Zhaozhen Wu et al.
Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can also...
Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients [0.03%]
基于液滴数字pcr技术检测egfr突变非小细胞肺癌患者咳痰样本中egfr活化及耐药突变
Klaus Hackner,Anna Buder,Maximilian J Hochmair et al.
Klaus Hackner et al.
Background: Proof of the T790M resistance mutation is mandatory if patients with EGFR-mutated non-small cell lung cancer (NSCLC) progress under first- or second-generation tyrosine kinase inhibitor therapy. In addition to...
The Role and Clinical Effectiveness of Multiline Chemotherapy in Advanced Desmoplastic Small Round Cell Tumor [0.03%]
多线化疗在解剖学小残留病态及复发性弥漫性小圆细胞肿瘤中的作用及临床疗效分析
Hyehyun Jeong,Yong Sang Hong,Young-Hoon Kim et al.
Hyehyun Jeong et al.
Background: A multimodal approach is the standard treatment for desmoplastic small round cell tumor (DSRCT); however, many patients are diagnosed with inoperable disease, which leaves chemotherapy as the only treatment op...
The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase [0.03%]
兔出血症病毒溶瘤抗软组织肉瘤活性由核糖核苷酸还原酶过表达介导
Yanghee Woo,Susanne G Warner,Rula Geha et al.
Yanghee Woo et al.
Background: Myxoma virus (MYXV) is an oncolytic poxvirus that lacks the gene for 1 of the subunits of ribonucleotide reductase (RR), a crucial DNA synthesis and repair enzyme. The overexpression of RR has been implicated ...
Sheng Yu,Ruilin Wang,Hong Tang et al.
Sheng Yu et al.
Immunotherapy, as a novel treatment, has brought new hope to many patients with cancer, including patients with lung cancer. However, the overall cure rate and survival rate of lung cancer are still not satisfactory. The process of evolutio...
Immunotherapy Induced Myasthenic-Like Syndrome in a Metastatic Melanoma Patient With Amyotrophic Lateral Sclerosis [0.03%]
一名患有肌萎缩性侧索硬化症的转移性黑色素瘤患者出现免疫治疗诱导的重症肌无力样综合征
Muhammad Jaffer,Matthew Chung,Esha Sharda et al.
Muhammad Jaffer et al.
Immunotherapy agents such as ipilimumab and nivolumab are immensely effective in the treatment of various malignancies. Despite this, neurologic immune-related sequelae (NIRS) have been observed. Prompt diagnosis and treatment is critical t...
Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? [0.03%]
预测淋巴瘤对检查点抑制剂的反应：我们达到了实体肿瘤的标准了吗？
Ah-Reum Jeong,Edward D Ball,Aaron Michael Goodman
Ah-Reum Jeong
Treatment of cancer has transformed with the introduction of checkpoint inhibitors. However, the majority of solid tumor patients do not respond to checkpoint blockade. In contrast, the response rate to programmed cell death 1 (PD-1) blocka...
Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation [0.03%]
交叉配型作为肝细胞癌受者在活体肝移植术后复发和生存期不良的免疫肿瘤学风险因素：进一步研究的呼吁
Cheng-Maw Ho,Rey-Heng Hu,Yao-Ming Wu et al.
Cheng-Maw Ho et al.
Background: The success of immunotherapy for patients with hepatocellular carcinoma (HCC) suggests that immune dysregulation occurs in HCC patients. This warrants an immuno-oncological risk assessment in the platform of l...
CDX2 Expression and Prognostic Factors of Resectable Pulmonary Large Cell Neuroendocrine Carcinoma [0.03%]
可手术肺大面积类神经内分泌癌的CDX2表达及预后因素分析
Ryo Mori,Shin-Ichi Yamashita,Kensuke Midorikawa et al.
Ryo Mori et al.
Background and aim: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare neoplasm, and its clinical features and management are still limited. We evaluated the clinicopathological factors, including CDX2 immuno...